These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 29848281

  • 1. In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3β.
    Mishra P, Kesar S, Paliwal SK, Chauhan M, Madan K.
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):150-158. PubMed ID: 29848281
    [Abstract] [Full Text] [Related]

  • 2. Discovery of Novel GSK-3β Inhibitors Using Pharmacophore and Virtual Screening Studies.
    Balakrishnan N, Raj JS, Kandakatla N.
    Interdiscip Sci; 2016 Sep; 8(3):303-11. PubMed ID: 26298578
    [Abstract] [Full Text] [Related]

  • 3. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
    El Kerdawy AM, Osman AA, Zaater MA.
    J Mol Model; 2019 May 25; 25(6):171. PubMed ID: 31129879
    [Abstract] [Full Text] [Related]

  • 4. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
    Natarajan P, Priyadarshini V, Pradhan D, Manne M, Swargam S, Kanipakam H, Bhuma V, Amineni U.
    J Recept Signal Transduct Res; 2016 Oct 25; 36(5):445-58. PubMed ID: 27305963
    [Abstract] [Full Text] [Related]

  • 5. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
    Benghanem S, Mesli F, Fatima Zohra HA, Nacereddine C, Hadjer C, Abdellatif M.
    J Biomol Struct Dyn; 2024 Sep 25; 42(14):7091-7106. PubMed ID: 37498130
    [Abstract] [Full Text] [Related]

  • 6. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS, Balaji B, Rani P, Ramanathan M.
    J Mol Graph Model; 2014 Sep 25; 53():31-47. PubMed ID: 25064440
    [Abstract] [Full Text] [Related]

  • 7. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
    Dessalew N, Bharatam PV.
    Chem Biol Drug Des; 2006 Sep 25; 68(3):154-65. PubMed ID: 17062013
    [Abstract] [Full Text] [Related]

  • 8. Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM/MM docking studies.
    Reddy KK, Singh SK, Tripathi SK, Selvaraj C.
    SAR QSAR Environ Res; 2013 Sep 25; 24(7):581-95. PubMed ID: 23521430
    [Abstract] [Full Text] [Related]

  • 9. (Z)-2-(3-Chlorobenzylidene)-3,4-dihydro-N-(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3β inhibitor: Identification by virtual screening and its validation in enzyme- and cell-based assay.
    Joshi P, Gupta M, Vishwakarma RA, Kumar A, Bharate SB.
    Chem Biol Drug Des; 2017 Jun 25; 89(6):964-971. PubMed ID: 27896926
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
    Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N.
    J Med Chem; 2008 Apr 10; 51(7):2062-77. PubMed ID: 18324764
    [Abstract] [Full Text] [Related]

  • 12. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J, Huang D, Zhao W, Ge H, Luo HB, Xu J.
    J Chem Inf Model; 2011 Jun 27; 51(6):1431-8. PubMed ID: 21615159
    [Abstract] [Full Text] [Related]

  • 13. Revisiting the Proposition of Binding Pockets and Bioactive Poses for GSK-3β Allosteric Modulators Addressed to Neurodegenerative Diseases.
    Silva GM, Borges RS, Santos KLB, Federico LB, Francischini IAG, Gomes SQ, Barcelos MP, Silva RC, Santos CBR, Silva CHTP.
    Int J Mol Sci; 2021 Jul 31; 22(15):. PubMed ID: 34361017
    [Abstract] [Full Text] [Related]

  • 14. Biological evaluation and energetic analyses of novel GSK-3β inhibitors.
    Zhang D, Liu L, Pang L, Jin Q, Ke K, Hu M, Yang J, Ma W, Xie H, Chen X.
    J Cell Biochem; 2018 Apr 31; 119(4):3510-3518. PubMed ID: 29144001
    [Abstract] [Full Text] [Related]

  • 15. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK, Ghate M, Goel A.
    J Mol Graph Model; 2013 May 31; 42():17-25. PubMed ID: 23507201
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
    Kumar A, Srivastava G, Negi AS, Sharma A.
    J Biomol Struct Dyn; 2019 Feb 31; 37(2):275-290. PubMed ID: 29310523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.